skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8799

Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran

Review

(1842) Views  (871) Full article downloads

Authors: Philippe Courtet

Published Date August 2010 Volume 2010:6(Supplement 1) Pages 3 - 8
DOI: http://dx.doi.org/10.2147/NDT.S11774

Philippe Courtet
CHRU Montpellier, Inserm U888, University of Montpellier I, Montpellier, France

Abstract: Suicidal behavior (SB) represents a major public health issue. Clinical and basic research suggests that SB is a specific entity in psychiatric nosology involving a combination of personality traits, genetic factors, childhood abuse and neuroanatomical abnormalities. The principal risk factor for suicide is depression. More than 60% of patients who complete suicide are depressed at the time of suicide, most of them untreated. There has been a controversy concerning a possible increased risk of SB in some depressed patients treated with antidepressants. Most recent evidence suggests, however, that treatment of depressed patients is associated with a favorable benefit-risk ratio. A recent study has determined the effects of 6 weeks of antidepressant treatment with the serotonin and norepinephrine reuptake inhibitor, milnacipran, on suicidality in a cohort of 30 patients with mild to moderate depression. At baseline, mild suicidal thoughts were present in 46.7% of patients. Suicidal thoughts decreased progressively throughout the study in parallel with other depressive symptoms and were essentially absent at the end of the study. At no time during treatment was there any indication of an increased suicidal risk. Retardation and psychic anxiety decreased in parallel possibly explaining the lack of any “activation syndrome” in this study.

Keywords: suicide, milnacipran, SNRI, activation syndrome






 

Other articles by Dr Mike Briley

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Antidepressant therapy with milnacipran and venlafaxine
Choking risk among psychiatric inpatients
Editorial Foreword - Milnacipran: recent findings in depression
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Milnacipran: a unique antidepressant?
Milnacipran: recent findings in depression
Noradrenergic symptom cluster in depression
Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
The importance of norepinephrine in depression
The increasing burden of depression
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran


Readers of this article also read:

Novel research translates to clinical cases of schizophrenic and cocaine psychosis
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Milnacipran: a unique antidepressant?
Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
Hyperbaric oxygen ameliorates worsening signs and symptoms of post-traumatic stress disorder
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Moderate alcohol consumption and cognitive risk
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
The GENACIS project: a review of findings and some implications for global needs in women-focused substance abuse prevention and intervention